🇺🇸 Neuromuscular Blocking Agents in United States

7 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 7

Most-reported reactions

1. Drug Ineffective — 1 report (14.29%)
2. Hypertension — 1 report (14.29%)
3. Myopathy — 1 report (14.29%)
4. Quadriplegia — 1 report (14.29%)
5. Respiratory Depression — 1 report (14.29%)
6. Rhabdomyolysis — 1 report (14.29%)
7. Tachycardia — 1 report (14.29%)

Source database →

Frequently asked questions

Is Neuromuscular Blocking Agents approved in United States?

Neuromuscular Blocking Agents does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Neuromuscular Blocking Agents in United States?

Fondazione Policlinico Universitario Agostino Gemelli IRCCS is the originator. The local marketing authorisation holder may differ — check the official source linked above.